Unknown

Dataset Information

0

Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof.


ABSTRACT: The discovery that aberrant activity of Janus kinase 2 (JAK2) is a driver of myeloproliferative neoplasms (MPNs) has led to significant efforts to develop small molecule inhibitors for this patient population. Ruxolitinib and fedratinib have been approved for use in MPN patients, while baricitinib, an achiral analogue of ruxolitinib, has been approved for rheumatoid arthritis. However, structural information on the interaction of these therapeutics with JAK2 remains unknown. Here, we describe a new methodology for the large-scale production of JAK2 from mammalian cells, which enabled us to determine the first crystal structures of JAK2 bound to these drugs and derivatives thereof. Along with biochemical and cellular data, the results provide a comprehensive view of the shape complementarity required for chiral and achiral inhibitors to achieve highest activity, which may facilitate the development of more effective JAK2 inhibitors as therapeutics.

SUBMITTER: Davis RR 

PROVIDER: S-EPMC8327781 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof.

Davis Ryan R RR   Li Baoli B   Yun Sang Y SY   Chan Alice A   Nareddy Pradeep P   Gunawan Steven S   Ayaz Muhammad M   Lawrence Harshani R HR   Reuther Gary W GW   Lawrence Nicholas J NJ   Schönbrunn Ernst E  

Journal of medicinal chemistry 20210211 4


The discovery that aberrant activity of Janus kinase 2 (JAK2) is a driver of myeloproliferative neoplasms (MPNs) has led to significant efforts to develop small molecule inhibitors for this patient population. Ruxolitinib and fedratinib have been approved for use in MPN patients, while baricitinib, an achiral analogue of ruxolitinib, has been approved for rheumatoid arthritis. However, structural information on the interaction of these therapeutics with JAK2 remains unknown. Here, we describe a  ...[more]

Similar Datasets

| S-EPMC6764664 | biostudies-literature
| S-EPMC6764664 | biostudies-literature
| S-EPMC6935287 | biostudies-literature
| S-EPMC9813003 | biostudies-literature
| S-EPMC8395186 | biostudies-literature
| S-EPMC7072561 | biostudies-literature
| S-EPMC7317815 | biostudies-literature
| S-EPMC11643516 | biostudies-literature